康辰药业公告，控股股东刘建华先生将其质押给中国银河证券股份有限公司的420万无限售条件流通股 办理了解除质押，占其所持股份比例为8.43%，占公司总股本比例为2.64%。解除质押时间为2025年10 月9日。目前，刘建华先生累计质押公司股份数量为464.68万股，占其持股数量比例为9.33%，占公司总 股本比例为2.92%。 ...

特此公告。 北京康辰药业股份有限公司董事会 2025 年 10 月 10 日 单位：万元 序 号 受托方 名称 产品名称 起始日 认购 金额 产品期 限（天） 赎回情况 本金 金额 收益 金额 1 中国银 河证券 股份有 限公司 "银河金鑫"收 益凭证633期-二 元自动看涨赎回 （上海金） 2025年4 月23日 3,000 156 3,000 57.70 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京康辰药业股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召 开的第四届董事会第十三次会议、第四届监事会第十一次会议审议通过《关于使 用闲置募集资金进行现金管理的议案》，同意公司使用额度不超过人民币 3 亿元 的闲置募集资金适时进行现金管理，该额度自公司董事会审议通过之日起 12 个 月内有效，并在有效期内可循环滚动使用。具体内容详见公司于 2024 年 10 月 30 日在上海证券交易所网站及指定信息披露媒体披露的《康辰药业关于使用闲 置募集资金进行现金 ...

一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 证券代码：603590 证券简称：康辰药业 公告编号：临 2025-056 北京康辰药业股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 控股股东及其一致行动人保证向本公司提供的信息真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 2.信息披露义务人信息 | | | 1、本次权益变动为股东履行此前披露的减持计划，不触及要约收购。本次 股东权益变动事项不涉及信息披露义务人披露权益变动报告书。 2、本次权益变动系股东的正常减持行为，不会对公司治理结构及持续经营 产生重大影响，本次权益变动不会导致公司控股股东及实际控制人发生变化。 3、本次权益变动后，股 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-055 北京康辰药业股份有限公司 高级管理人员减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 高级管理人员持股的基本情况 本次减持计划实施前，北京康辰药业股份有限公司（以下简称"公司"）高 级管理人员牛战旗持有公司股份 350,000 股，占公司总股本的 0.2196%。 减持计划的实施结果情况 减持计划实施完毕 | 股东名称 | 牛战旗 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 减持计划首次披露日期 | 2025 年 8 | 月 | 28 | 日 | | | | | 减持数量 | 87,500股 | | | | | | | | 减持期间 | 年 2025 9 | 月 | 18 | 日～2025 | 年 | 月 9 | 日 29 | | 减持方式及对应减持数 | 集中竞价减持，87,500 | | | | 股 | | | | 量 ...

南财智讯9月30日电，康辰药业公告，公司高级管理人员牛战旗在2025年9月18日至2025年9月29日期 间，通过集中竞价交易方式累计减持公司股份8.75万股，占公司总股本的0.05%，减持价格区间为52.72 至59.25元/股，减持总金额为493.48万元。本次减持计划已实施完毕，减持后牛战旗持有公司股份26.25 万股，占公司总股本的0.16%。 ...

康辰药业公告，高级管理人员牛战旗原持有35万股，占公司总股本0.2196%；2025年9月18日至2025年9 月29日通过集中竞价累计减持87500股，占公司总股本0.0549%，减持价52.72～59.25元/股，减持总金额 493.48万元。本次减持计划已实施完毕，牛战旗现持股26.25万股，占总股本0.1647%。 ...

第1笔成交价格为48.09元，成交14.00万股，成交金额673.26万元，溢价率为-10.61%，买方营业部为中 信证券股份有限公司客户资产管理部，卖方营业部为中国银河证券股份有限公司北京中关村大街证券营 业部。 第2笔成交价格为48.09元，成交33.00万股，成交金额1,586.97万元，溢价率为-10.61%，买方营业部为中 信证券股份有限公司客户资产管理部，卖方营业部为中国银河证券股份有限公司北京中关村大街证券营 业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第6笔成交价格为48.09元，成交6.30万股，成交金额302.97万元，溢价率为-10.61%，买方营业部为华泰 证券股份有限公司北京分公司，卖方营业部为中国银河证券股份有限公司北京中关村大街证券营业部。 9月30日，康辰药业收涨0.69%，收盘价为53.80元，发生7笔大宗交易，合计成交量95.9万股，成交金额 4611.84万元。 第3笔成交价格为48.09元，成交20.00万股，成交金额961.80万元，溢价率为-10.61%，买方营业部为中 信证券股份有限公司客户资产管理部，卖方营业部为中国银河证券 ...

| 交易日期 | 证券調称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 1586.97 | 33 | 空部落ち發展貫音 | | M | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 961.8 | 20 | 品 - 品品是有限公司 | 有限公司 1999 | ਨੂੰ | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 673.26 | 14 | 公司 2019 11:30 | | 물 | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 673.26 | 14 | 菜就是这些品番 | | KA | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 302.97 | 6.3 | 华泰国有限公司限 | 有限公司北 | 질 | | 2 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Company Summary - KC1036 is a class 1 innovative chemical drug independently developed by the company, with global intellectual property rights [1] - The drug exerts anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting of VEGFR to suppress tumor cell growth [1] - By inhibiting AXL, KC1036 can enhance the host's anti-tumor immune response, thereby preventing immune evasion by tumors [1] - Currently, KC1036 is undergoing clinical research for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric Ewing sarcoma, with over 300 subjects enrolled in the clinical studies to date [1] - Preliminary clinical results indicate significant anti-tumor activity, along with good safety and tolerability [1]